ARENSIA is a German operator of professional research clinics, dedicated to performing early phase clinical trials - Phase IB, IIA, and PROOF OF CONCEPT - with novel compounds. Our trials involve a wide range of patient populations.
ARENSIA clinics are designed to enable patient's access to innovative therapies early in the drug development process. Patient's safety and comfort are of paramount importance at ARENSIA.
Our facilities are strategically located within or adjacent to large university/private hospitals in the following cities: Phoenix, Arizona USA, Bucharest and Cluj-Napoca in Romania, Chisinau in Moldova, Tbilisi in Georgia, Kyiv in Ukraine and Sofia in Bulgaria.
Due to its dedicated research-oriented infrastructure, ARENSIA achieves a time reduction of avg. 60% through unrivalled recruiting performance vs. typical clinical trial sites which are overcrowded by daily hospital duties, lack of staff, competition for the same populations, and long timelines for contract negotiations.
The shortened time and the different setup of concentrating effort on a few ARENSIA Clinics (instead of the traditional high number of sites) lead to an overall budget reduction of 50% for a typical Phase IB/IIA PROOF OF CONCEPT trial.
93% repeat business proves that ARENSIA’s value proposition is the long-expected disruptive breakthrough in time and cost! This has allowed our continuous growth while collaborating with the leading pharmaceutical companies worldwide, numerous biotechs, as well as global CROs.
Industry
Research Services, Medical and pharmaceutical research, Research and testing, IT, Internet, R&D, Training courses NES, Education and training, Education, Training & Organisations, Exhibition and conference organisers, Services to businesses, Business Services
HQ Location
Merowingerplatz 1
Duesseldorf, North Rhine-Westphalia 40225, DE
Keywords
First into Patients Phase Ib SAD/MAD trialsProof of Concept studiesPhase I PK trials in patients with renal and hapatic impairment (mildmoderatesevere)Translational medicinePhase IIa trialsAdaptive design protocolsDDI trials in patientsQTc trials in patients